HK Stock Market Move | LAENA-B(02105) has risen by over 6% again, with a total increase of 36% over the past three trading days. The preliminary results of the LAE102 Phase I clinical MAD study are positive.

LAEKNA-B(02105) surged over 6%, with a cumulative increase of 36% over the past three trading days. As of the time of writing, it has risen by 6.11% to HK$17.55, with a trading volume of 1.18 billion Hong Kong dollars. On the news front, Laikna Pharmaceutical announced that the Phase I Multiple Ascending Dose study (MAD study) of LAE102 for the treatment of obesity in China has achieved positive preliminary results. The preliminary results show an encouraging trend of lean muscle mass increase and fat reduction. By the 5th week, the average lean body weight of the subjects in the LAE102 6mg/kg dose group increased by 1.7% compared to baseline, while the average fat mass also decreased by 2.2%. After adjusting for the placebo control group, the average lean body weight increased by 4.6% and the average fat mass decreased by 3.6%. Additionally, it was recently reported that Eli Lilly has stopped the combination trial of bimagrumab, with some analysts suggesting that bimagrumab's withdrawal from the diabetes trial weakens potential competition and highlights the value of the LAE102 pipeline in collaboration with Eli Lilly. DBS Bank has reiterated a "buy" rating on Laikna Pharmaceutical, primarily due to the significant increase in the likelihood of Eli Lilly licensing the company's LAE102 muscle loss prevention drug. Clinical trial information released by Eli Lilly in late September indicates that the competitive advantage of LAE102 for this indication may be more prominent than expected. In addition, the Phase I clinical trial of LAE102 is expected to be completed in September, and the subsequent data release is likely to generate interest from Eli Lilly and other international pharmaceutical companies for licensing agreements.